Search / Trial NCT06234670

Risk Factors and A Prediction Model of Recurrence of Uterine Fibroids

Launched by WENWEN WANG · Jan 28, 2024

Trial Information

Current as of October 08, 2024

Not yet recruiting

Keywords

Uterine Fibroid Recurrence Risk Factor Prediction Medel

Description

Uterine fibroids are the most common benign tumors of female reproductive organs during childbearing age. With the emphasis on fertility preservation and the pursuit of the physical integrity, about 46% of patients prefer the conservative surgery which preserves the uterus. However, the high recurrence rate of uterine fibroids after conservative surgery does cause formidable clinical problems. According to the literature, the recurrence rate is about 11.7% at one year after myomectomy and would increase steadily. At the eighth year of myomectomy, the recurrence rate is as high as 84.4%. Du...

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age:18-50 years
  • 2. Diagnosed with uterine fibroids (by ultrasound or pathology)
  • 3. Accept myomectomy.
  • 4. Complete clinical data.
  • Exclusion Criteria:
  • 1. Severe infectious disease
  • 2. Previous history of malignant tumors
  • 3. Incomplete clinical data.
  • 4. Pregnant

About Wenwen Wang

Wenwen Wang is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative therapeutic interventions. With a focus on rigorous study design and ethical standards, Wenwen Wang leads initiatives that encompass a wide range of therapeutic areas. The sponsor prioritizes collaboration with research institutions and healthcare professionals to ensure the integrity and efficacy of clinical trials. Through meticulous planning and execution, Wenwen Wang aims to contribute valuable insights to the scientific community and enhance the development of safe and effective treatments.

Locations

Wuhan, None Selected, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0